financetom
Business
financetom
/
Business
/
CoStar Q3 Earnings, Revenue Rise; Updates 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CoStar Q3 Earnings, Revenue Rise; Updates 2025 Guidance
Oct 28, 2025 2:12 PM

04:47 PM EDT, 10/28/2025 (MT Newswires) -- CoStar Group ( CSGP ) reported Q3 adjusted earnings late Tuesday of $0.23 per diluted share, up from $0.22 a year earlier.

Analysts polled by FactSet expected $0.18.

Revenue for the quarter ended Sept. 30 was $833.6 million, up from $692.6 million a year earlier.

Analysts surveyed by FactSet expected $813.2 million.

For Q4, the company expects adjusted EPS of $0.26 to $0.28 on revenue of $885 million to $895 million. Analysts expected $0.28 and $857.6 million, respectively.

For the full year, it now expects adjusted EPS of $0.82 to $0.84 on revenue of $3.23 billion to $3.24 billion.

Its previous guidance was for adjusted EPS of $0.76 to $0.80 on revenue of $3.14 billion to $3.16 billion.

Analysts expected $0.80 and $3.18 billion, respectively.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canada Nickel to Spin Out Net Smelter Returns on Certain Properties
Canada Nickel to Spin Out Net Smelter Returns on Certain Properties
Mar 18, 2025
08:35 AM EDT, 03/18/2025 (MT Newswires) -- Canada Nickel ( CNIKF ) on Tuesday said it created a new royalty company to hold net smelter return (NSR) royalties on most of its regional exploration properties in the Timmins Nickel district. The company signed a binding letter of intent with Edmiston Drive Capital (EDCC) to create the new company called RoyaltyCo....
RedHill Biopharma Plans to File for UK Approval of H.Pylori Treatment
RedHill Biopharma Plans to File for UK Approval of H.Pylori Treatment
Mar 18, 2025
08:01 AM EDT, 03/18/2025 (MT Newswires) -- RedHill Biopharma ( RDHL ) said Tuesday it intends to file a UK Marketing Authorisation Application for Talicia, which is used to treat helicobacter pylori infections. The application will reference the FDA's approval of Talicia through the MHRA's expedited International Recognition Procedure and should be approved by Q4, the company said. The company's...
Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy
Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy
Mar 18, 2025
08:37 AM EDT, 03/18/2025 (MT Newswires) -- Actinium Pharmaceuticals ( ATNM ) said Tuesday it is launching a clinical program consisting of trials studying Actimab-A in combination with either Merck's ( MRK ) Keytruda or Bristol Myers Squibb's ( BMY ) Opdivo for the treatment of multiple solid tumors. Actimab-A is meant to improve the efficacy of the immunotherapies by...
Ocugen Advances OCU200 Trial After Safety Board Review
Ocugen Advances OCU200 Trial After Safety Board Review
Mar 18, 2025
08:30 AM EDT, 03/18/2025 (MT Newswires) -- Ocugen ( OCGN ) said Tuesday that an independent safety board reviewed data from the first dosing group in its phase 1 trial of OCU200 for diabetic macular edema and approved advancing to the second group. The company said the trial is testing OCU200, a fusion protein combining two human proteins, in patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved